626 related articles for article (PubMed ID: 19502112)
1. Immunogenicity of rituximab in patients with severe pemphigus.
Schmidt E; Hennig K; Mengede C; Zillikens D; Kromminga A
Clin Immunol; 2009 Sep; 132(3):334-41. PubMed ID: 19502112
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.
Pfütze M; Eming R; Kneisel A; Kuhlmann U; Hoyer J; Hertl M
Dermatology; 2009; 218(3):237-45. PubMed ID: 19088461
[TBL] [Abstract][Full Text] [Related]
3. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
4. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
[TBL] [Abstract][Full Text] [Related]
5. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
[TBL] [Abstract][Full Text] [Related]
6. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.
Abasq C; Mouquet H; Gilbert D; Tron F; Grassi V; Musette P; Joly P
Arch Dermatol; 2009 May; 145(5):529-35. PubMed ID: 19451496
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.
Carvalho R; Maio P; Cunha D; Freitas I; Afonso A; Cardoso J
Eur J Dermatol; 2011; 21(3):415-6. PubMed ID: 21527367
[No Abstract] [Full Text] [Related]
8. [Juvenile pemphigus vulgaris].
Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P
Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695
[TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
[TBL] [Abstract][Full Text] [Related]
10. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
[TBL] [Abstract][Full Text] [Related]
11. Pemphigus vegetans Neumann type with anti-desmoglein and anti-periplakin autoantibodies.
Cozzani E; Christana K; Mastrogiacomo A; Rampini P; Drosera M; Casu M; Murialdo G; Parodi A
Eur J Dermatol; 2007; 17(6):530-3. PubMed ID: 17951135
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
Czernik A; Beutner EH; Bystryn JC
J Am Acad Dermatol; 2008 May; 58(5):796-801. PubMed ID: 18423257
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
[TBL] [Abstract][Full Text] [Related]
14. Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development?
Torzecka JD; Woźniak K; Kowalewski C; Waszczykowska E; Sysa-Jedrzejowska A; Pas HH; Narbutt J
Arch Dermatol Res; 2007 Aug; 299(5-6):239-43. PubMed ID: 17534636
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus.
Mentink LF; de Jong MC; Kloosterhuis GJ; Zuiderveen J; Jonkman MF; Pas HH
Br J Dermatol; 2007 Apr; 156(4):635-41. PubMed ID: 17263817
[TBL] [Abstract][Full Text] [Related]
16. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M
Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825
[TBL] [Abstract][Full Text] [Related]
17. Delayed response of oral pemphigus vulgaris to rituximab treatment.
Niedermeier A; Wörl P; Barth S; Schuler G; Hertl M
Eur J Dermatol; 2006; 16(3):266-70. PubMed ID: 16709491
[TBL] [Abstract][Full Text] [Related]
18. Detection of pemphigus desmoglein 1 and desmoglein 3 autoantibodies and pemphigoid BP180 autoantibodies in saliva and comparison with serum values.
Andreadis D; Lorenzini G; Drakoulakos D; Belazi M; Mihailidou E; Velkos G; Mourellou-Tsatsou O; Antoniades D
Eur J Oral Sci; 2006 Oct; 114(5):374-80. PubMed ID: 17026501
[TBL] [Abstract][Full Text] [Related]
19. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
Feldman RJ; Christen WG; Ahmed AR
Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
